Latest Lion Point Capital, LP Stock Portfolio

Lion Point Capital, LP Performance:

2025 Q4: 11.14%YTD: 17.04%2024: -31.55%

Performance for 2025 Q4 is 11.14%, and YTD is 17.04%, and 2024 is -31.55%.

About Lion Point Capital, LP and 13F Hedge Fund Stock Holdings

On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Lion Point Capital, LP reported an equity portfolio of $19.3 Millions as of 31 Dec, 2025.

The top stock holdings of Lion Point Capital, LP are MIST, PRAX, MLTX. The fund has invested 7.9% of it's portfolio in MILESTONE PHARMACEUTICALS IN and 6.8% of portfolio in PRAXIS PRECISION MEDICINES I.

The fund managers got completely rid off AVADEL PHARMACEUTICALS PLC and INSMED INC (INSM) stocks. They significantly reduced their stock positions in MERSANA THERAPEUTICS INC (MRSN), ARCUTIS BIOTHERAPEUTICS INC (ARQT) and MINERALYS THERAPEUTICS INC. Lion Point Capital, LP opened new stock positions in CUE BIOPHARMA INC (CUE), SAREPTA THERAPEUTICS INC (SRPT) and VENTYX BIOSCIENCES INC (VTYX). The fund showed a lot of confidence in some stocks as they added substantially to HUMACYTE INC (HUMA), BIOHAVEN LTD and JASPER THERAPEUTICS INC (JSPR).

Lion Point Capital, LP Annual Return Estimates Vs S&P 500

Our best estimate is that Lion Point Capital, LP made a return of 11.14% in the last quarter. In trailing 12 months, it's portfolio return was 17.04%.

Performance
S&P 500

New Buys

Ticker	$ Bought
cue biopharma inc	672,752
sarepta therapeutics inc	613,320
ventyx biosciences inc	374,745
lantheus hldgs inc	366,025
dyne therapeutics inc	352,080
uniqure nv	351,771
pacira pharmaceuticals inc	349,380
viatris inc	344,865

New stocks bought by Lion Point Capital, LP

Additions

Ticker	% Inc.
humacyte inc	498
biohaven ltd	127
jasper therapeutics inc	16.67
seres therapeutics inc	16.33
geron corp	15.6
milestone pharmaceuticals in	14.65

Additions to existing portfolio by Lion Point Capital, LP

Reductions

Ticker	% Reduced
mersana therapeutics inc	-99.61
arcutis biotherapeutics inc	-85.13
mineralys therapeutics inc	-73.08
bridgebio pharma inc	-62.41
regenxbio inc	-53.94
syndax pharmaceuticals inc	-34.55
disc medicine inc	-23.58
praxis precision medicines i	-21.93

Lion Point Capital, LP reduced stake in above stock

Sold off

Ticker	$ Sold
avadel pharmaceuticals plc	-911,619
kiniksa pharmaceuticals intl	-908,622
insmed inc	-900,063

Lion Point Capital, LP got rid off the above stocks

Sector Distribution

Lion Point Capital, LP has about 90.3% of it's holdings in Healthcare sector.

Sector	%
Healthcare	90.3
Others	9.7

Market Cap. Distribution

Lion Point Capital, LP has about 8% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
SMALL-CAP	43.4
MICRO-CAP	17.8
MID-CAP	12.5
UNALLOCATED	9.7
NANO-CAP	8.6
LARGE-CAP	8

Stocks belong to which Index?

About 48.1% of the stocks held by Lion Point Capital, LP either belong to S&P 500 or RUSSELL 2000 index.

Index	%
Others	51.9
RUSSELL 2000	46.3
S&P 500	1.8

Top 5 Winners (%)		%
SPRB	spruce biosciences inc	873.3 %
PRAX	praxis precision medicines i	406.1 %
MRSN	mersana therapeutics inc	136.9 %
MLTX	moonlake immunotherapeutics	83.8 %
RGNX	regenxbio inc	36.0 %

Top 5 Winners ($)		$
PRAX	praxis precision medicines i	1.2 M
MLTX	moonlake immunotherapeutics	0.4 M
MRSN	mersana therapeutics inc	0.3 M
SNDX	syndax pharmaceuticals inc	0.3 M
BBIO	bridgebio pharma inc	0.2 M

Top 5 Losers (%)		%
HUMA	humacyte inc	-32.1 %
JSPR	jasper therapeutics inc	-21.8 %
MCRB	seres therapeutics inc	-21.4 %
	biohaven ltd	-19.2 %
FENC	fennec pharmaceuticals inc	-17.0 %

Top 5 Losers ($)		$
JSPR	jasper therapeutics inc	-0.2 M
HUMA	humacyte inc	-0.2 M
FENC	fennec pharmaceuticals inc	-0.2 M
	biohaven ltd	-0.1 M
MCRB	seres therapeutics inc	-0.1 M

Lion Point Capital, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Lion Point Capital, LP

Lion Point Capital, LP has 39 stocks in it's portfolio. About 48.5% of the portfolio is in top 10 stocks. JSPR proved to be the most loss making stock for the portfolio. PRAX was the most profitable stock for Lion Point Capital, LP last quarter.

Last Reported on: 17 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ARDX	ardelyx inc	3.88	128,650	750,030	reduced	-20.95

ARQT	arcutis biotherapeutics inc	0.79	5,250	152,460	reduced	-85.13

AZTA	azenta inc	1.67	9,700	322,622	new

BBIO	bridgebio pharma inc	1.98	5,000	382,450	reduced	-62.41

BNTC	benitec biopharma inc	4.32	62,000	835,140	unchanged	0.00

CMPS	compass pathways plc	2.07	58,000	400,200	unchanged	0.00

CUE	cue biopharma inc	3.48	2,202,850	672,752	new

DAWN	day one biopharmaceuticals i	2.03	42,000	391,440	unchanged	0.00

DYN	dyne therapeutics inc	1.82	18,000	352,080	new

EWTX	edgewise therapeutics inc	1.17	9,100	225,817	new

FENC	fennec pharmaceuticals inc	4.48	112,434	865,742	reduced	-8.59

GERN	geron corp	3.95	578,000	762,960	added	15.6

GHRS	gh research plc	0.67	10,200	129,540	new

HUMA	humacyte inc	2.48	500,000	480,250	added	498

INSM	insmed inc	0.00	0.00	0.00	sold off	-100

INVA	innoviva inc	0.85	8,200	163,918	new

IPHA	innate pharma s a	0.74	81,151	142,014	new

JANX	janux therapeutics inc	1.36	19,000	262,200	new

JSPR	jasper therapeutics inc	4.40	465,000	850,950	added	16.67

KURA	kura oncology inc	2.47	46,000	477,940	unchanged	0.00